Our data showed that treatment of certain erbB2+ breast cancer cell lines with MM-121 resulted in a dramatic inhibition on PI-3K/Akt signaling, the major determinant of trastuzumab resistance in breast cancer [27]. This evidence concerns the gene ERBB2 and breast carcinoma.